Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161

Jenny Mjösberg(University of Amsterdam), Sara Trifari(La Jolla Institute for Immunology), Natasha K. Crellin(La Jolla Institute for Immunology), Charlotte P. Peters(University of Amsterdam), Cornelis M. van Drunen(University of Amsterdam), Berber Piet(Academic Medical Center), Wytske J. Fokkens(University of Amsterdam), Tom Cupedo(Erasmus MC), Hergen Spits(University of Amsterdam)
Nature Immunology
September 11, 2011
Cited by 1,152Open Access
Full Text

Abstract

Mice have lineage-negative IL-7Rα+ (innate lymphoid) cells that contribute to type 2 immunity. Spits and colleagues identify a similar CRTH2+CD161+ population in human lungs and gut that produces IL-13 after stimulation. Innate lymphoid cells (ILCs) are emerging as a family of effectors and regulators of innate immunity and tissue remodeling. Interleukin 22 (IL-22)- and IL-17-producing ILCs, which depend on the transcription factor RORγt, express CD127 (IL-7 receptor α-chain) and the natural killer cell marker CD161. Here we describe another lineage-negative CD127+CD161+ ILC population found in humans that expressed the chemoattractant receptor CRTH2. These cells responded in vitro to IL-2 plus IL-25 and IL-33 by producing IL-13. CRTH2+ ILCs were present in fetal and adult lung and gut. In fetal gut, these cells expressed IL-13 but not IL-17 or IL-22. There was enrichment for CRTH2+ ILCs in nasal polyps of chronic rhinosinusitis, a typical type 2 inflammatory disease. Our data identify a unique type of human ILC that provides an innate source of T helper type 2 (TH2) cytokines.


Related Papers

No related papers found

Powered by citation graph analysis